MST Financial is proud to have supported Lumos Diagnostics Holdings (LDX.ASX) its $20 million placement, acting as Joint Lead Manager to the offer.
The placement received strong support from both existing and new institutional investors, with demand significantly exceeding the $20 million target. The funds will be used to scale manufacturing capacity and support the commercial launch of FebriDx across the US point-of-care market, following the recent CLIA waiver granted by the US FDA.
This milestone is transformative for Lumos Diagnostics Holdings, opening access to a US$1 billion+ market across over 300,000 locations and approximately 80 million patients annually, a 15x increase in the addressable market for FebriDx.
hashtag#MSTFinancial hashtag#LumosDiagnostics hashtag#FebriDx hashtag#HealthcareInnovation hashtag#ASX hashtag#CapitalMarkets hashtag#PointOfCare hashtag#MedicalDiagnostics
